Amgen Inc. (AMGN) vs Novo Nordisk A/S (NVO)
Amgen Inc. and Novo Nordisk A/S are both Drug Manufacturers General companies. Amgen Inc. is the larger, with a market value of $219.1B against $129.3B — 1.7× the size. Novo Nordisk A/S trades at the lower P/E: 9.5× against 25.6×. Novo Nordisk A/S grew revenue faster over the last twelve months: 13.2% against 9.10%. Novo Nordisk A/S has the higher net margin (35.5% vs 23.0%) and the higher return on invested capital (28.7% vs 13.0%). Both pay a dividend; Amgen Inc. yields more (3.16% vs 1.36%). Across the 23 metrics below, Novo Nordisk A/S leads on 18 and Amgen Inc. on 5.
Valuation
Profitability
| Metric | AMGN | NVO | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 69.52% | 80.73% | 72.77% |
| Operating margin | 29.99% | 43.36% | 18.90% |
| Net margin | 22.95% | 35.47% | 8.27% |
| Free cash flow margin | 26.71% | 14.79% | 17.25% |
| Return on equity | 91.47% | 60.84% | 6.97% |
| Return on assets | 9.53% | 22.00% | 2.76% |
| Return on invested capital | 12.98% | 28.67% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack